-
2 weeks ago | 
labiotech.eu | Clara Fernandez |Clara Fernández
Subscribe to our newsletter to get the latest biotech news!By clicking this I agree to receive Labiotech's newsletter and understand that my personal data will be processed according to the Privacy Policy.*NameThis field is for validation purposes and should be left unchanged. Since the approval of the first-ever gene therapy for blindness, there has been a wave of biotechs developing gene therapy treatments with the potential to cure different forms of genetic vision loss.
-
Feb 11, 2025 | 
insideprecisionmedicine.com | Clara Fernandez |Clara Fernández |Kathy Vuksanaj
Precision medicine has largely been driven by rapid progress in genomics over the past two decades, with advances in next-generation sequencing enabling massive parallelization with unprecedented speed. However, interest is now increasingly shifting toward proteomics to gather insights into the underlying mechanisms of disease. After all, it is proteins that execute the instructions encoded in our genes and are largely responsible for the myriad of cellular processes that keep us alive.
-
Jan 30, 2025 | 
outsourcing-pharma.com | Clara Fernandez |Clara Fernández |Jonathan Smith
Munich-based biotechnology company Ethris has announced encouraging topline data from a phase 1 clinical trial evaluating its lead messenger RNA (mRNA) candidate, ETH47. The therapy is intended for the treatment of uncontrolled asthma, a condition where asthma symptoms are frequent and disruptive, often due to a virus infection. The mechanism of action of ETH47 aims to prevent the symptoms of uncontrolled asthma at the source by inducing an innate immune response at the point of entry of viruses.
-
Jan 30, 2025 | 
outsourcing-pharma.com | Jonathan Smith |Clara Fernandez |Clara Fernández
The US radiopharmaceuticals giant Lantheus is snapping up the Contract Development and Manufacturing (CDMO) Evergreen Theragnostics as it expands its radiopharmaceuticals business. The deal, which is expected to close in late 2025, is intended to absorb Evergreen’s manufacturing capabilities and radiopharmaceutical pipeline.
-
Jan 28, 2025 | 
outsourcing-pharma.com | Jonathan Smith |Clara Fernandez |Clara Fernández |Liza Laws
The round was led by the US venture capital (VC) firm General Catalyst Partners with participation from compatriot VC Greylock Partners in addition to strategic investors. Manas will use the proceeds to scale up its AI technology and drive ahead its drug pipeline programs. Manas AI is one of many startups gunning to address the costly and risky process of drug development, with more than 90% of drug candidates failing to reach the market from the preclinical stage.
-
Jan 28, 2025 | 
outsourcing-pharma.com | Clara Fernandez |Clara Fernández
Novo Nordisk has reported weight loss effects of up to 22% in patients who received a weekly subcutaneous dose of its next-generation weight loss drug, amycretin, over the course of 36 weeks. These topline results show early potential for the drug candidate to surpass the efficacy of Eli Lilly’s Zepbound (tirzepatide), one of its major competitors in the weight loss drug market.
-
Jan 23, 2025 | 
outsourcing-pharma.com | Clara Fernandez |Clara Fernández |Liza Laws
Compared to the previous years, 2024 has been a relatively slow year for mergers and acquisitions in the pharmaceutical space. The largest acquisition of 2024 doesn’t nearly match Pfizer’s acquisition of Seagen for $43 billion in 2023, or Amgen’s Horizon buyout for $27.8 billion in 2022.
-
Jan 21, 2025 | 
outsourcing-pharma.com | Clara Fernandez |Clara Fernández |Liza Laws
Results from the STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight loss effects the drug is known for. Novo Nordisk has announced topline results from the phase 3b trial STEP UP, which investigated the effects of two doses of Wegovy (semaglutide) in over 1,400 patients over the course of 72 weeks. Both formulations were delivered subcutaneously once a week and were accompanied by lifestyle changes.
-
Jan 17, 2025 | 
outsourcing-pharma.com | Clara Fernandez |Clara Fernández |Jonathan Smith
Ashley Davidson, vice president of sponsor and tech strategy at Advarra, discusses her outlook for this year’s edition of the SCOPE summit. The global market for clinical trials is expected to grow to over $106 bn by 2032, but stakeholders in this industry face increasingly challenging obstacles, including regulatory hurdles, talent shortages and clinical studies becoming significantly larger, longer, and more complex.
-
Jan 16, 2025 | 
outsourcing-pharma.com | Jonathan Smith |Clara Fernandez |Clara Fernández |Liza Laws
As pharmaceutical pipelines and R&D investments expand worldwide, the global market for clinical trials is projected to grow by almost 9% per year from $48.2 billion in 2023 to $73.2 billion in 2028, partly driven by soaring demand for outsourced trial providers. However, clinical trial providers are facing challenges in completing trials efficiently, including long trial durations, increased competition for sites and participants, and complex protocols.
